Last month, we asked HOW MANY STATE MEDICAID PROGRAMS (out of 50) COVER CGM FOR PEOPLE WITH TYPE-1
Answer: 14 states. For those doing the math, that equates to just 28% of states in the U.S.Congratulations to Jenn Velez, a pump, CGM, and soon-to-be-hybrid-closed-loop user from Wallkill, NY. Jenn was the first person to provide the correct answer.
NEW QUESTION for MARCH:
It seems that the top-selling insulin in 2019 was Sanofi’s Lantus (glargine), with $4.1 billion in sales. Humalog (lispro) and Novolog (aspart) were 2nd and 3rd, with $3.0B and 2.8B in sales respectively.
But the #1 diabetes medication generated just over $5.5 billion in sales last year. What was it?
*The first person to submit the correct answer wins their choice of book from our in-store or online bookstore.